Peace broke out last week between gene sequencing rivals Illumina Inc. and Qiagen N.V. But before lawyers could pack up their files, a new patent war was taking shape.
On Friday, Illumina, Columbia University and its licensee Qiagen settled their 5-year-old patent litigation. Qiagen agreed to stop using with its GeneReader machine a method for labeling nucleic acid molecules that was patented by Illumina.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
